Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 16 member 13 (SLC16A13, also known as monocarboxylate transporter 13 or MCT13) is a proton-linked transporter belonging to the SLC16 family of monocarboxylate transporters, responsible for transporting monocarboxylic acids such as lactate across cellular membranes[5][7]. It is an orphan transporter, meaning its full substrate profile and physiological functions are not completely characterized[6]. SLC16A13 is expressed in human tissues including the Golgi apparatus and cytosol, and is implicated in energy metabolism, particularly related to glucose and lipid regulation[2][4]. Genetic studies have linked SLC16A13 variants to increased susceptibility for type 2 diabetes and hepatic steatosis through effects on hepatic insulin sensitivity and lipid accumulation[2]. There are currently no established drugs directly targeting this transporter, and its precise role in disease and therapy remains under investigation[2][5][6][7].
Proton-linked transport of monocarboxylates (e.g., lactate, possibly others) across plasma membrane
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 16 member 13 (SLC16A13 (also MCT13)).